Merck KGaA, Darmstadt, Germany announced that the first patient received dosing in its phase 3 clinical program evaluating enpatoran for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE